News

Filter

Current filters:

GenericsAnti-virals

1 to 9 of 77 results

Strides Arcolab to make and distribute Gilead’s TAF

20-01-2015

Indian drugmaker Strides Arcolab Limited has entered into a licensing agreement with US biotech major…

Anti-viralsGenericsGilead SciencesLicensingProductionStrides Arcolabtenofovir alafenamide

FDA grants tentative approval to Mylan's two dosages of abacavir/lamivudine tablets for pediatric HIV

FDA grants tentative approval to Mylan's two dosages of abacavir/lamivudine tablets for pediatric HIV

05-12-2014

The US Food and Drug Administration has granted tentative approval for New Drug Applications by US generic…

Abacavir Sulfate and Lamivudine TabletsAnti-viralsGenericsMylanRegulationUSA

District Court rules not to prevent Dr Reddy's and Endo from challenging Ranbaxy

District Court rules not to prevent Dr Reddy's and Endo from challenging Ranbaxy

21-11-2014

Indian pharma company Ranbaxy has been denied its request to prevent the US Food and Drug Administration…

Anti-viralsDr Reddy's LaboratoriesEndo InternationalGastro-intestinalsGenericsLegalNexiumRanbaxy LaboratoriesUSAValcyte

FDA revokes tentative approval of Ranbaxy’s generic Nexium and Valcyte

07-11-2014

Indian generics drugmaker Ranbaxy Laboratories revealed in a Bombay Stock Exchange filing that it has…

Anti-viralsAstraZenecaGastro-intestinalsGenericsNexiumPfizerRanbaxy LaboratoriesRegulationSun PharmaceuticalUSAValcyte

Mylan debuts generic Viramune XR in USA

Mylan debuts generic Viramune XR in USA

31-10-2014

US generic drugmaker Mylan said yesterday that it has launched its nevirapine extended-release tablets,…

Anti-viralsBoehringer IngelheimGenericsMarkets & MarketingMylanUSAViramune

Mylan debuts generic of ViiV’s Combivir in USA

Mylan debuts generic of ViiV’s Combivir in USA

06-10-2014

US generic drugmaker Mylan has launched of its Lamivudine and Zidovudine Tablets USP, 15mg/300mg, which…

Anti-viralsCombivirGenericsGlaxoSmithKlineMarkets & MarketingMylanUSAViiV Healthcare

1 to 9 of 77 results

Back to top